预期收购事项亦将进一步丰富集团的金融工具及业务模式，并推广本集团影像解决方案服务业务的创新赋能解决方案。此外，目标公司亦可作为集团与医疗器械制造商及平台商间的桥梁，从而拓宽集团影像解决方案服务业务的发展渠道，为集团寻求更多业务伙伴。Gelonghui, November 1, 丨 Yimai Sunshine (02522.HK) announced that on November 1, 2024, Yimai Sunshine Health Management (a wholly-owned subsidiary of the company), the seller Gongqingcheng Fanghou No.1 Investment Partnership (limited partnership), target companies Shanghai Ronggongshe Fanghou Technology Co., Ltd., Fanghou Investment and Fanghou 2 entered into an equity transfer agreement to trade 18.0% of the target company's shares. The cost of the acquisition is RMB 17.28 million and will be paid to the seller in a lump sum in cash upon completion by Yimai Sunshine Health Management. Yimai Sunshine Health Management will cover the costs of the acquisition from the Group's internal financial resources.
The target company is a limited company incorporated under Chinese law and an innovative fintech company focused on the medical industry. The target company uses its self-developed medical supply chain software-as-a-service (SaaS) platform to provide customers in the medical device distribution chain (including medical device platform providers and financial institutions) with comprehensive “financial+technology+medical technology” enabling solutions (such as supply chain management and financial services).
Since its establishment, the Group has been committed to becoming a medical imaging platform operator and manager in China that provides diversified imaging services and values for the entire medical imaging industry chain. In particular, the Group's imaging solutions service business is positioned to export core imaging products and capabilities to all participants in the medical imaging industry chain. After the acquisition is completed, with the target company's innovative financial service solutions and extensive resource networks of medical device manufacturers and platform providers, the Group expects to further expand its reach and coverage of industry chain participants and obtain more potential business opportunities.
It is anticipated that the acquisition will also further enrich the Group's financial instruments and business model, and promote innovative enabling solutions for the Group's imaging solutions service business. In addition, target companies can also act as a bridge between the Group and medical device manufacturers and platform providers, thereby broadening the development channels of the Group's imaging solution service business and seeking more business partners for the Group.
